PMC full text:
Published online 2016 Mar 8. doi: 10.1186/s13045-016-0253-6
Fig. 5
![An external file that holds a picture, illustration, etc.
Object name is 13045_2016_253_Fig5_HTML.jpg An external file that holds a picture, illustration, etc.
Object name is 13045_2016_253_Fig5_HTML.jpg](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784359/bin/13045_2016_253_Fig5_HTML.jpg)
Metformin synergized with sorafenib to suppress angiogenesis, proliferation, and EMT but promote apoptosis in vivo. Representative images of tumor sections were stained with antibody against CD31, Ki67, and TUNEL (magnification ×200). a Metformin in combination with sorafenib synergistically minimized both Ki67 and CD31 expression but promoted TUNEL expression. b Combined therapy inhibited EMT at protein level which lysated from the tumor tissue, and pAMPK expression was elevated both in metformin group and combined treatment groups. c Combined treatment of metformin and sorafenib suppressed HIF-2α protein expression but upregulated TIP30 protein expression evaluated by Western blot